Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase EARLY_PHASE1 1Phase 1 1

Status

Recruiting 29Active not recruiting 26Completed 5Withdrawn 4Not yet recruiting 4Terminated 1Suspended 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 7Genitourinary 6CNS 6Other hematologic neoplasm 5Lymphoid 4Gynecologic 4Breast 4Thoracic 3Sarcoma 3Dermatologic 3Plasma cell 2Myeloid 2Head & Neck 2Tumor-Agnostic 1Other solid neoplasm 1Other 1

Conditions

Pancreatic Neoplasms 2Ovarian Neoplasms 2Uterine Cervical Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Platinum-Refractory Fallopian Tube Carcinoma 1Neoplasm Metastasis 1Melanoma 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

Paclitaxel 20Carboplatin 20Bevacizumab 13Radiotherapy 12Cisplatin 11Cyclophosphamide 8olaparib 6niraparib 6Taxes 6pembrolizumab 5Magnetic Resonance Spectroscopy 5Gemcitabine 5Biopsy 5talazoparib 4dostarlimab 4aldesleukin 4Specimen Handling 4Fulvestrant 4Doxorubicin 4fludarabine 3atezolizumab 3Topotecan 3Radiation 3NVP-BKM120 3Methods 3Metformin 3Letrozole 3Hyperthermic Intraperitoneal Chemotherapy 3Early Intervention, Educational 3Colposcopy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Withdrawn × Specimen Handling × Gynecologic × Clear all
NCT06626256 2025-12-24

STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma

City of Hope Medical Center

Phase 1 Withdrawn
DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT06393751 2025-06-03

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
GynecologicSarcoma

Platinum-Refractory Fallopian Tube Carcinoma

NCT05672095 2025-05-23

Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer

City of Hope Medical Center

Phase 1/2 Withdrawn
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡